Small interfering RNA for cancer treatment: overcoming hurdles in delivery.

Authors :: Charbe, Nitin Bharat
Amnerkar, Nikhil D.
Ramesh, B.
Tambuwala, Murtaza M.
Bakshi, Hamid A.
Aljabali, Alaa A.A.
Khadse, Saurabh C.
Satheeshkumar, Rajendran
Satija, Saurabh
Metha, Meenu
Chellappan, Dinesh Kumar
Shrivastava, Garima
Gupta, Gaurav
Negi, Poonam
Dua, Kamal
Zacconi, Flavia C.
Source :: Acta Pharmaceutica Sinica B; Nov2020, Vol. 10 Issue 11, p2075-2109, 35p
Publication Year :: 2020
Abstract: In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies. The latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells were highlighted. It also provides the necessary information about siRNA development and its mechanism of action. Image 1 [ABSTRACT FROM AUTHOR]